研究单位：[1]BeiGene[2]Mayo Clinic Arizona,Phoenix,Arizona,United States,85254[3]Sarah Cannon Research Institute (SCRI) Florida Cancer Specialist South,Fort Myers,Florida,United States,33901[4]Mayo Clinic Jacksonville,Jacksonville,Florida,United States,32224[5]University of Miami Sylvester Comprehensive Cancer Center,Miami,Florida,United States,33136[6]Sarah Cannon Research Institute (SCRI) - Florida Cancer Specialist North,Saint Petersburg,Florida,United States,33901[7]Sarah Cannon Research Institute (SCRI) Florida Cancer Specialist Panhandle,Tallahassee,Florida,United States,32308[8]Sarah Cannon Research Institute (SCRI) Florida Cancer Specialist East,West Palm Beach,Florida,United States,33401[9]University of Kansas Medical Center Research Institute,Kansas City,Kansas,United States,66160[10]University of Minnesota,Minneapolis,Minnesota,United States,55455[11]Mayo Clinic, Rochester,Rochester,Minnesota,United States,55905[12]Rutgers-Cancer Institute of New Jersey,New Brunswick,New Jersey,United States,08901[13]Montefiore Einstein Center for Cancer Care,Bronx,New York,United States,10461[14]Gabrail Cancer Center Research,Canton,Ohio,United States,44718[15]Providence Portland,Portland,Oregon,United States,97213[16]UPMC Cancer Pavillion,Pittsburgh,Pennsylvania,United States,15232[17]Sarah Cannon Research Institute (SCRI),Nashville,Tennessee,United States,37203[18]Medical College of Wisconsin,Milwaukee,Wisconsin,United States,53226[19]Blacktown Hospital,Blacktown,New South Wales,Australia,2146[20]Chris O'Brien Lifehouse,Camperdown,New South Wales,Australia,2050[21]Pindara Private Hospital,Benowa,Queensland,Australia,4217[22]Icon Cancer Foundation,South Brisbane,Queensland,Australia,4101[23]Metro South Health, Cancer Trials Unit Division of Cancer Services - PAH,Woolloongabba,Queensland,Australia,4102[24]Tennyson Centre Day Hospital,Adelaide,South Australia,Australia,5037[25]Adelaide Cancer Centre (Ashford Cancer Centre (ACC)) - 480 Specialist Centre,Adelaide,South Australia,Australia,5087[26]Royal Hobart Hospital (RHH),Hobart,Tasmania,Australia,7000[27]Bendigo Health,Bendigo,Victoria,Australia,2550[28]Monash Hospital,Clayton,Victoria,Australia,3168[29]St Vincent''s Hospital,Fitzroy,Victoria,Australia,3065[30]Linear Clinical Research,Perth,Western Australia,Australia,6009[31]St John of God - Subiaco Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC),Subiaco,Western Australia,Australia,6008[32]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[33]Chinese PLA General Hospital,Beijing,Beijing,China,100039[34]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China,100050[35]Beijing Cancer Hospital,Beijing,Beijing,China,100142[36]Beijing TongRen Hospital,Beijing,Beijing,China,100176[37]Beijing Luhe Hospital, Capital Medical University,Beijing,Beijing,China,350014[38]Sichuan Cancer Hospital and Institute,Sichuan,Chengdu,China,610042[39]Chongqing Cancer Hospital,Chongqing,Chongqing,China,400030[40]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[41]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[42]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450003[43]Hubei Cancer Hospital,Wuhan,Hubei,China,400037[44]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[45]Hunan Cancer Hospital,Changsha,Hunan,China,410013[46]The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou,Jiangsu,China,215008[47]Jilin Cancer Hospital,Changchun,Jilin,China,132000[48]Jinan Central Hospital,Jinan,Shandong,China,250013[49]Shandong provincial Qianfoshan Hospital,Jinan,Shandong,China[50]WeiFang People''s Hospital,Weifang,Shandong,China,261000[51]The First Affiliated Hospital Of Xi''an Jiao Tong University,Xi''an,Shanxi,China,710061[52]Tianjin Medical Universi
The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b is to assess overall response rate (ORR) determined by Investigator per RECIST v1.1 for patients in each dose- expansion cohort
